A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline ...

Topline data were announced from two pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-controlled ...

One of the most closely watched pipeline assets is povorcitinib, a JAK1 inhibitor being developed for hidradenitis suppurativa (HS) and other dermatological conditions. Pivotal data for ...

Along with vitiligo, povorcitinib is also in phase 3 testing for hidradenitis suppurativa, and phase 2 for prurigo nodularis, chronic spontaneous urticaria, and asthma. New Boehringer US Head ...

One of the most closely watched pipeline assets is povorcitinib, a JAK1 inhibitor being developed for hidradenitis suppurativa (HS) and other dermatological conditions. Pivotal data for povorcitinib ...

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised ...

Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Certain soaps and other skin care products may irritate hidradenitis suppurativa (HS), whereas others can help manage the condition and its symptoms. HS is a chronic skin condition that causes ...

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor ...

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, ...